Six Agenda Items Approved, Including Appointment of a New Inside Director

Kim Kyung-Ah, President and CEO of Samsung Epis Holdings, emphasized her intention to establish a foundation for long-term growth by expanding the company's new drug development business at the first regular shareholders' meeting since the company's establishment.


On March 20, Samsung Epis Holdings held its inaugural regular shareholders' meeting at Songdo Convensia in Yeonsu-gu, Incheon. During the meeting, a total of six agenda items were presented and approved, including the approval of the first fiscal year’s financial statements, appointment of inside directors and audit committee members, and approval of director remuneration limits. Samsung Epis Holdings further strengthened its responsible management system to enhance expertise and transparency in decision-making by newly appointing Executive Vice President Kim Hyungjun, former Head of Business Support at Samsung Bioepis, as an inside director.


Kim Kyung-Ah, President and CEO of Samsung Epis Holdings, is speaking at the first regular shareholders' meeting held on the 20th at Songdo Convensia in Yeonsu-gu, Incheon. Samsung Epis Holdings

Kim Kyung-Ah, President and CEO of Samsung Epis Holdings, is speaking at the first regular shareholders' meeting held on the 20th at Songdo Convensia in Yeonsu-gu, Incheon. Samsung Epis Holdings

View original image

In her welcoming remarks, President Kim stated, “We are working to expand into the new drug development sector based on the capabilities we have accumulated through our biosimilar business. Our first new drug candidate, an antibody-drug conjugate (ADC), has received clinical trial plan approval from the U.S. Food and Drug Administration (FDA) and is preparing to enter global clinical trials.”


She further added, “Based on research into the next-generation bio-technology platform conducted by our subsidiary EpisnextLab, we plan to expand new business opportunities such as joint research and technology transfer with global pharmaceutical companies. As a bio-investment holding company, we will continue to invest in research and development and pursue global collaboration to build a long-term growth foundation and enhance shareholder value.”



Samsung Epis Holdings is a bio holding company that was officially launched in November 2025. It owns two subsidiaries: Samsung Bioepis, a biopharmaceutical development company established in February 2012, and EpisnextLab, a technology platform development company established in November 2025.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing